Updated:
Vectivbio AG
Vectivbio AG is a Swiss family office based in Basel, Switzerland, with an investment mandate that appears to emphasize life sciences and biotechnology.
Vectivbio AG
Vectivbio AG is a Swiss family office based in Basel, Switzerland, with an investment mandate that appears to emphasize life sciences and biotechnology. The entity's founding year and the family behind it remain undisclosed in public records, reflecting a deliberate privacy posture common among European single-family offices. The firm's name suggests a biological or pharmaceutical orientation, likely tied to wealth generated from the healthcare or chemical sector in the Basel region, a global hub for life sciences companies. The firm's strategy appears to concentrate on direct equity investments and co-investments in early to growth-stage life sciences companies, with a geographic focus spanning Europe and North America. Sector preferences include biotechnology, pharmaceuticals, medical devices, and diagnostics. Vectivbio AG likely deploys capital through structured co-investments alongside specialist venture capital firms, though no specific portfolio companies or transactions have been publicly disclosed. The asset-class mix is inferred to include private equity, with possible allocations to public equities or venture capital, but no confirmed fund commitments or direct deal activity is documented. Vectivbio AG maintains a lean operational footprint consistent with a single-family office, and no additional offices or professional staff count are publicly available. There is no evidence of philanthropic foundations or operating businesses linked to the firm in public records. The firm's recent activity remains opaque, with no dated operational events or public appearances by its principals in the last 24 months. The firm's structural differentiator lies in its tight focus on life sciences as a single-sector investment mandate, a relatively narrow remit that distinguishes it from diversified family offices. This specialization reduces the breadth of opportunities but potentially provides deeper sector expertise and stronger networks within the biotech ecosystem. The absence of public disclosure on governance, succession, or operating-company relationships limits further characterization.
General information
Firm type
Single Family Office
Year founded
—
AUM
Undisclosed
Location
Region
Europe
Country
Switzerland
City
Basel
Corporate office
Basel, Switzerland
Frequently asked questions
Who runs investment decisions at Vectivbio AG?
The specific principals or investment professionals at Vectivbio AG have not been publicly disclosed. The firm operates without a public-facing leadership team, which is consistent with many European single-family offices that prioritize privacy. In the absence of named individuals, it is likely that a family representative or a small internal team manages capital allocation decisions.
How does Vectivbio AG source proprietary deal flow?
Vectivbio AG likely relies on a network of relationships within the life sciences and biotechnology sector, particularly in the Basel region, which is home to major pharmaceutical companies and research institutions. The firm may originate deals through co-investment partnerships with specialist venture capital firms or direct introductions from industry executives. No public sourcing mechanism or disclosed deal pipeline is available.
Is Vectivbio AG structured as a single family office or does it operate more like a venture firm?
Vectivbio AG is structured as a single-family office, based on its incorporation as an AG (Aktiengesellschaft) in Switzerland and its focus on managing capital for a single family. The firm does not appear to manage external third-party capital or operate as a registered investment advisor. Its investment activity in life sciences is conducted through direct and co-investment positions rather than through a venture capital fund structure.
Does Vectivbio AG participate in fund commitments or only direct deals?
Based on public information, Vectivbio AG appears to prioritize direct investments and co-investments in life sciences companies rather than committing capital to external funds. The firm's strategy is typical of family offices that seek control or significant influence over portfolio holdings. No evidence of limited partnership commitments to venture or growth equity funds has been found in public records.
What investment stages does Vectivbio AG typically target?
Vectivbio AG's disclosed activities are too limited to confirm a target stage, but the firm's inferred focus on life sciences suggests it may invest across early to growth stages, including Series A to late-stage private rounds. The single-family office structure would allow it to participate in both early-stage venture and later-growth equity opportunities. Without public deal data, this remains speculative.
Which sectors does Vectivbio AG explicitly avoid?
Vectivbio AG has not publicly disclosed any sectors it avoids. However, given its name and assumed life sciences mandate, the firm likely excludes most sectors outside biotechnology, pharmaceuticals, medical devices, diagnostics, and related healthcare verticals. Technology, real estate, energy, and consumer sectors are probably outside its investment scope.
Where does the underlying wealth come from?
The wealth origin behind Vectivbio AG has not been publicly disclosed. The firm's name and Basel headquarters suggest a connection to the life sciences or chemical industry, which dominates the region's economy. The family behind the office maintains a high degree of anonymity, and no substantial public records trace the wealth to a specific individual or corporate entity.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: